This e-learning module addresses the effects of SGLT2 inhibition in cardiorenal syndrome. Member registration (free) is needed to enroll in this course.
Prof. Zannad gives an overview of CV outcome trials with SGLT2 inhibitors; first in diabetes patients and now with results in HF patients in the DAPA-HF trial.
Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.
SGLT2 inhibitors reduce CV endpoints most likely through a reduction of HF-related events. Prof. Marx discusses mechanisms potentially explaining the beneficial effects of this drug class on HF.